{"protocolSection":{"identificationModule":{"nctId":"NCT05951101","orgStudyIdInfo":{"id":"CLN002"},"organization":{"fullName":"AuriGen Medical Ltd","class":"INDUSTRY"},"briefTitle":"Zenith LAA Occlusion System","officialTitle":"Evaluation of the Safety and Performance of the Zenith LAA Occlusion System and Procedure for the Mechanical Closure of the Left Atrial Appendage (LAA)"},"statusModule":{"statusVerifiedDate":"2024-01","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-02-07","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2024-05-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2025-07-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-06-29","studyFirstSubmitQcDate":"2023-07-11","studyFirstPostDateStruct":{"date":"2023-07-18","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-01-17","lastUpdatePostDateStruct":{"date":"2024-01-18","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"AuriGen Medical Ltd","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Demonstrate the safety and performance of the Zenith LAA Occlusion System and procedure to occlude the Left Atrial Appendage (LAA) from the left atrium (LA) using a minimally invasive technique.\n\nIndication - LAA closure in patients with non-valvular atrial fibrillation, with an ostial diameter between 18 mm and 26 mm","detailedDescription":"The study objective is to demonstrate the safety and performance of the Zenith LAA Occlusion System and procedure to occlude the Left Atrial Appendage (LAA) from the left atrium (LA) using a minimally invasive technique."},"conditionsModule":{"conditions":["Atrial Fibrillation","Left Atrial Appendage","Stroke"],"keywords":["LAA Occlusion","Left Atrial Appendage","Atrial Fibrillation","LAA closure"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","interventionModelDescription":"Implantation of Zenith LAA Occlusion System","primaryPurpose":"DEVICE_FEASIBILITY","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":10,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Zenith LAA Occlusion System","type":"EXPERIMENTAL","description":"Zenith LAA Occlusion System Implantation","interventionNames":["Device: Zenith LAA Occlusion System"]}],"interventions":[{"type":"DEVICE","name":"Zenith LAA Occlusion System","description":"LAA closure in patients with non-valvular atrial fibrillation, with an ostial diameter between 17 mm and 25 mm","armGroupLabels":["Zenith LAA Occlusion System"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Procedural success","description":"Acute procedural success is defined as the delivery and release of the Zenith LAA Occlusion System in the target location (LAA) without any device or procedure related serious adverse events until the post-procedure discharge or 72 hours (whichever comes first)","timeFrame":"72 hours"},{"measure":"Mechanical device closure","description":"Mechanical device closure - residual jet around the device ≤5 mm at 45 days by TOE","timeFrame":"45 days"}],"secondaryOutcomes":[{"measure":"Device related thrombus","description":"LAAO device-related thrombus as assessed by TOE at 45 days and by CCTA at 12 months","timeFrame":"45 days and 12 months"},{"measure":"SAE","description":"All SAEs device and/or procedure-related post-procedure and to the end of the study","timeFrame":"through study completion, an average of 1 year"},{"measure":"Stroke","description":"Ischemic stroke through 12 months","timeFrame":"12 months"},{"measure":"Thromboembolism","description":"Systemic thromboembolism through 12 months","timeFrame":"12 months"},{"measure":"Device closure","description":"Mechanical device closure - residual jet around the device ≤5 mm at 6 months (if it is not achieved at 45 Days)","timeFrame":"6 months"},{"measure":"Device use questionnaire","description":"Use of the Zenith LAA Occlusion System per Device use questionnaire (Operator)","timeFrame":"up to 24 hours"},{"measure":"Changes in Quality of Life score according to SF-12 questionnaire","description":"Patient-reported health quality at Baseline, 45 days, 6 months, and 12 months","timeFrame":"Baseline, 45 days, 6 months and 12 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age ≥18 and ≤80 years at the time of screening\n2. Documented diagnosis of non-valvular AF\n3. Clinical indication for LAA occlusion\n4. Willing and able to return to and comply with scheduled follow-up visits and testing, including medical treatment as required by the protocol.\n5. Willing and able to provide written informed consent\n\nExclusion Criteria:\n\nWithin 30 days before the procedure date:\n\n1. Exhibited NYHA class III or IV heart failure symptoms\n2. Known bleeding disorders (such as bleeding diathesis, thrombocytopenia \\[platelet count \\<100 X 109/L\\], severe anaemia \\[haemoglobin of \\<8 g/dL\\], or INR \\>2 \\[spontaneous\\])\n\n   Within 90 days before the procedure date:\n3. Documented history of myocardial infarction or unstable angina\n4. Documented embolic stroke, TIA or suspected neurologic event\n5. Chronic renal insufficiency (eGFR ≤15mL/min per 1.73 m2 (CKD-EPI)) or end-stage renal disease\n6. Requires long-term oral anticoagulation therapy for a condition other than AF\n7. Diagnosed active local or systemic infection, septicaemia, active pericarditis, or fever of unknown origin\n8. Known acquired or inherited propensity for forming blood clots (e.g., malignancy and factor V Leiden mutation) established by prior objective testing\n9. Contraindication to the standard of care post-implantation antithrombotic medication regime (e.g., dual antiplatelet therapy (DAPT)/direct oral anticoagulant (DOAC)\n10. Rheumatic heart disease\n11. Implanted mechanical valve prosthesis\n12. Documented carotid disease, defined as greater than 70% stenosis without symptoms or greater than 50% stenosis with symptoms\n13. Body mass index greater than 40 kg/m2\n14. Patient is pregnant or breastfeeding or plans/desires to get pregnant within the next 12 months post-procedure\n15. Current or planned enrolment in an investigation or study of an investigational device or investigational drug that would interfere with this study and the required follow-up\n16. Mental impairment or other psychiatric conditions which may not allow the patient to understand the nature, significance, and scope of the study\n17. Any other criteria (including physical and mental health), medical illness, or comorbidity which would make the subject unsuitable to participate in this study as determined by the clinical site principal investigator\n18. Patients with known allergy or sensitivity to nitinol (nickel and titanium) or any of the other materials in the Zenith LAA Occlusion System Implant\n19. Life expectancy of less than 1 year\n20. Inability, unwillingness, or contraindication to undergo Trans-Oesophageal and/or Trans-Thoracic Echocardiogram (TOE/TTE) or Cardiac Computed Tomography Angiography (CCTA) imaging or any catheterisation procedures\n21. Any anatomical condition that precludes the patient from undergoing LAA occlusion with the AuriGen Zenith LAA Occlusion System implant procedure, as determined by the principal investigator\n\n    Imaging Exclusion Criteria:\n22. Patients with a maximal ostial left atrial appendage diameter \\>25 mm or \\<17 mm by pre-procedural ECG-gated CT scan, to fit the Zenith LAA Occlusion System\n23. Patients where CCTA analysis suggests that the Zenith LAA Occlusion System may not be suitable\n24. Intracardiac thrombus diagnosed by CCTA or echocardiography\n25. Previous occlusion/ligation of the LAA (by any surgical or percutaneous method)\n26. Documented presence of implanted closure devices (e.g. Atrial septal defect (ASD), Patent foramen ovale (PFO) or Ventricular septal defect (VSD) device) for congenital defect treatment\n27. Documented Left Ventricular Ejection Fraction (LVEF) \\<30%","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Nuwani Edirisinghe","role":"CONTACT","phone":"+447581155987","email":"nuwani.edirisinghe@aurigenmedical.com"},{"name":"John Thompson","role":"CONTACT","phone":"+353 863525057","email":"john.thompson@aurigenmedical.com"}],"overallOfficials":[{"name":"Felix Mahfoud","affiliation":"Internal Medicine and Cardiology, Saarland University Hospital","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Christian Ukena","affiliation":"Saarland University Hospital","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Auckland City Hospital","city":"Auckland","country":"New Zealand","contacts":[{"name":"Mandy Fish","role":"CONTACT","phone":"+64 21 240 9349","email":"mfish@adhb.govt.nz"},{"name":"Matthew O'Connor, MA MB BChir FRACP","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":-36.84853,"lon":174.76349}},{"facility":"Christchurch Hospital","city":"Christchurch","country":"New Zealand","contacts":[{"name":"Catherine Cruickshank","role":"CONTACT","email":"catherine.cruickshank@cdhb.health.nz"},{"name":"Philip Adamson, MBChB PhD MPH FRACP FCSANZ","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":-43.53333,"lon":172.63333}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"}],"ancestors":[{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]}},"hasResults":false}